How to strengthen the presence of patients in health technology assessments conducted by the health authorities-Reference-Cited by-同舟云学术

How to strengthen the presence of patients in health technology assessments conducted by the health authorities

Published:2018-02 Issue:1 Volume:73 Page:95-105
ISSN:0040-5957
Container-title:Therapies
language:fr
Short-container-title:Therapies

Author:

Mamzer Marie-France,Dubois Sophie,Saout Christian,Albin Nicolas,Béhier Jehan-Michel,Buisson Anne,Diebolt Vincent,Delaitre Olivier,Duguet Christophe,Fagon Jean-Yves,Gaillard Ségolène,Le Jeunne Claire,Mazars René,Micallef Joëlle,Nabarette Hervé,Piazza Laurent,Raynaud Catherine,Varoqueaux Nathalie

Publisher

Elsevier BV

Subject

Pharmacology (medical)

Reference23 articles.

1. Legifrance. LOI no 2016–41 du 26 janvier 2016 de modernisation de notre système de santé. JORF no̊0022. 27 janvier 2016. https://www.legifrance.gouv.fr/eli/loi/2016/1/26/AFSX1418355L/jo, [Accessed 4 December 2017].

2. Global survey on health technology assessment by national authorities;Organisation mondiale de la santé,2015

3. Patient involvement in health technology assessment;Facey,2017

4. Constructing and contesting legitimacy and accountability in polycentric regulatory regimes;Black;Regulation & governance,2008

5. History of the international societies in health technology assessment: international society for technology assessment in health care and healthtechnology assessment international;Banta;Int J Technol Assess Health Care,2009

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HTA decision-making for drugs for rare diseases: comparison of processes across countries;Orphanet Journal of Rare Diseases;2022-07-08

2. Exploration of the visibility of patient input in final recommendation documentation for three health technology assessment bodies;International Journal of Technology Assessment in Health Care;2020-05-07

3. Collaboration between academics, small pharmaceutical company and patient organizations in the development of a new formulation of cysteamine in nephropathic cystinosis: A successful story;Therapies;2020-04

4. EVALUATION OF THE EXPEDIENCY OF TECHNOLOGY COMMERCIALIZATION: A CASE OF INFORMATION TECHNOLOGY AND BIOTECHNOLOGY;Technological and Economic Development of Economy;2020-01-24

5. Co‐construction of health technology assessment recommendations with patients: An example with cardiac defibrillator replacement;Health Expectations;2019-11-05